AR083422A1 - Composiciones y metodos para tratar la hipertension pulmonar - Google Patents
Composiciones y metodos para tratar la hipertension pulmonarInfo
- Publication number
- AR083422A1 AR083422A1 ARP110103833A ARP110103833A AR083422A1 AR 083422 A1 AR083422 A1 AR 083422A1 AR P110103833 A ARP110103833 A AR P110103833A AR P110103833 A ARP110103833 A AR P110103833A AR 083422 A1 AR083422 A1 AR 083422A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- ambrisentan
- tadalafil
- therapeutically effective
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 4
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 abstract 3
- 229960002414 ambrisentan Drugs 0.000 abstract 3
- 229960000835 tadalafil Drugs 0.000 abstract 3
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 102000010180 Endothelin receptor Human genes 0.000 abstract 1
- 108050001739 Endothelin receptor Proteins 0.000 abstract 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 229940127293 prostanoid Drugs 0.000 abstract 1
- 150000003814 prostanoids Chemical class 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
- 229960002578 sitaxentan Drugs 0.000 abstract 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 abstract 1
- 229960002381 vardenafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Formulaciones que comprenden cantidades terapéuticamente efectivas de ambrisentan o una sal farmacéuticamente aceptable del mismo y tadalafil o una sal farmacéuticamente aceptable del mismo y métodos para tratar y/o prevenir la hipertensión pulmonar por administración de las formulaciones.Reivindicación 1: Una formulación farmacéutica caracterizada porque comprende: una cantidad terapéuticamente efectiva de un antagonista selectivo del receptor de endotelina de tipo A (ERA) que se selecciona entre el grupo que consiste en ambrisentan, sitaxsentan y sales farmacéuticamente aceptables de los mismos, y una cantidad terapéuticamente efectiva de un inhibidor de fosfodiesterasa de tipo 5 (PDE5) que se selecciona entre el grupo que consiste en sildenafil, tadalafil, vardenafil y sales farmacéuticamente aceptables de los mismos, donde la proporción en peso entre el ERA selectivo de tipo A y el inhibidor de PDE5 se encuentra dentro del rango entre aproximadamente 1:1 y aproximadamente 1:10. Reivindicación 14: La formulación farmacéutica de la reivindicación 1, caracterizada porque además comprende un tercer agente activo que comprende por lo menos una droga que se selecciona entre el grupo que consiste en prostanoides, inhibidores de PDE5 diferentes del tadalafil, antagonistas del receptor de endotelina diferentes del ambrisentan, bloqueantes del canal de calcio, diuréticos, anticoagulantes, oxígeno y combinaciones de los mismos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39352910P | 2010-10-15 | 2010-10-15 | |
| US201161490454P | 2011-05-26 | 2011-05-26 | |
| US201161497475P | 2011-06-15 | 2011-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083422A1 true AR083422A1 (es) | 2013-02-21 |
Family
ID=45939010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103833A AR083422A1 (es) | 2010-10-15 | 2011-10-17 | Composiciones y metodos para tratar la hipertension pulmonar |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20120269898A1 (es) |
| EP (2) | EP2637664B1 (es) |
| JP (2) | JP5806320B2 (es) |
| KR (2) | KR20150002876A (es) |
| CN (1) | CN103458690B (es) |
| AR (1) | AR083422A1 (es) |
| AU (2) | AU2011315891B2 (es) |
| BR (1) | BR112013008983A2 (es) |
| CA (1) | CA2814518C (es) |
| CY (1) | CY1119007T1 (es) |
| DK (1) | DK2637664T3 (es) |
| EA (2) | EA201691759A1 (es) |
| ES (1) | ES2627944T3 (es) |
| HR (1) | HRP20170848T1 (es) |
| HU (1) | HUE033346T2 (es) |
| LT (1) | LT2637664T (es) |
| MX (1) | MX346730B (es) |
| NZ (2) | NZ610012A (es) |
| PL (1) | PL2637664T3 (es) |
| PT (1) | PT2637664T (es) |
| RS (1) | RS56135B1 (es) |
| SI (1) | SI2637664T1 (es) |
| SM (1) | SMT201700297T1 (es) |
| TW (1) | TWI542580B (es) |
| WO (1) | WO2012051559A2 (es) |
| ZA (1) | ZA201302746B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007333115B2 (en) | 2006-12-12 | 2013-01-10 | Gilead Sciences, Inc. | Composition for treating a pulmonary hypertension |
| HUE033346T2 (en) | 2010-10-15 | 2017-11-28 | Gilead Sciences Inc | Compositions and methods for treating pulmonary hypertension |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| WO2014174529A2 (en) * | 2013-04-23 | 2014-10-30 | Hetero Research Foundation | Polymorphs of avanafil |
| US20150125546A1 (en) * | 2013-11-06 | 2015-05-07 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
| CN105581990A (zh) * | 2014-08-27 | 2016-05-18 | 人福医药集团股份公司 | 安立生坦片剂及其制备方法 |
| WO2016149218A1 (en) * | 2015-03-13 | 2016-09-22 | Indiana University Research And Technology Corporation | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS |
| SI3496739T1 (sl) * | 2016-07-15 | 2021-06-30 | Acceleron Pharma Inc. | Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije |
| JP2020500183A (ja) * | 2016-10-27 | 2020-01-09 | プルモキネ、インコーポレイテッド | 肺高血圧症の治療のための併用療法 |
| WO2019010445A1 (en) * | 2017-07-07 | 2019-01-10 | The Regents Of The University Of Colorado, A Body Corporate | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PULMONARY HYPERTENSION |
| SG11202006080SA (en) | 2017-12-26 | 2020-07-29 | Ftf Pharma Private Ltd | Liquid oral formulations for pde v inhibitors |
| CN109406688A (zh) * | 2018-09-28 | 2019-03-01 | 中国食品药品检定研究院 | 用于检测产品中违禁药品的标准样品 |
| CN114728002A (zh) * | 2019-11-29 | 2022-07-08 | 埃科特莱茵药品有限公司 | 治疗肺动脉高血压的方法 |
| EP4076398A4 (en) | 2019-12-16 | 2024-01-03 | Tenax Therapeutics, Inc. | LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF) |
| KR102606504B1 (ko) * | 2020-04-10 | 2023-11-29 | 주식회사 대웅테라퓨틱스 | 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물 |
| CN112826944B (zh) * | 2021-01-29 | 2023-08-15 | 台州职业技术学院 | 一种安立生坦包合物及其制备方法 |
| EP4456897A4 (en) | 2021-12-31 | 2025-12-10 | Tenax Therapeutics Inc | ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| IL135462A0 (en) | 1997-11-12 | 2001-05-20 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| CA2572179A1 (en) | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| CN101072564A (zh) * | 2004-08-26 | 2007-11-14 | 恩希赛弗制药公司 | 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途 |
| EP2013208B1 (en) | 2006-04-21 | 2011-06-22 | Pfizer Products Inc. | Pyridin[3,4-b]pyrazinones |
| US20080139483A1 (en) * | 2006-12-12 | 2008-06-12 | Gorczynski Richard J | Drug combination for hypertensive disorders |
| AU2007333115B2 (en) | 2006-12-12 | 2013-01-10 | Gilead Sciences, Inc. | Composition for treating a pulmonary hypertension |
| CN101801936B (zh) | 2007-07-31 | 2012-10-03 | 吉利德科罗拉多公司 | 安立生坦的代谢物和衍生物 |
| WO2010062640A1 (en) | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
| HUE033346T2 (en) | 2010-10-15 | 2017-11-28 | Gilead Sciences Inc | Compositions and methods for treating pulmonary hypertension |
-
2011
- 2011-10-14 HU HUE11833507A patent/HUE033346T2/en unknown
- 2011-10-14 TW TW100137481A patent/TWI542580B/zh not_active IP Right Cessation
- 2011-10-14 EP EP11833507.4A patent/EP2637664B1/en not_active Revoked
- 2011-10-14 LT LTEP11833507.4T patent/LT2637664T/lt unknown
- 2011-10-14 JP JP2013534043A patent/JP5806320B2/ja not_active Expired - Fee Related
- 2011-10-14 AU AU2011315891A patent/AU2011315891B2/en active Active
- 2011-10-14 EP EP16180914.0A patent/EP3106163A1/en not_active Withdrawn
- 2011-10-14 KR KR20147032816A patent/KR20150002876A/ko not_active Ceased
- 2011-10-14 CN CN201180060879.3A patent/CN103458690B/zh not_active Expired - Fee Related
- 2011-10-14 BR BR112013008983A patent/BR112013008983A2/pt not_active IP Right Cessation
- 2011-10-14 PT PT118335074T patent/PT2637664T/pt unknown
- 2011-10-14 EA EA201691759A patent/EA201691759A1/ru unknown
- 2011-10-14 DK DK11833507.4T patent/DK2637664T3/en active
- 2011-10-14 EA EA201390428A patent/EA026074B1/ru active IP Right Revival
- 2011-10-14 CA CA2814518A patent/CA2814518C/en not_active Expired - Fee Related
- 2011-10-14 SI SI201131190A patent/SI2637664T1/sl unknown
- 2011-10-14 ES ES11833507.4T patent/ES2627944T3/es active Active
- 2011-10-14 NZ NZ610012A patent/NZ610012A/en active IP Right Revival
- 2011-10-14 US US13/274,013 patent/US20120269898A1/en not_active Abandoned
- 2011-10-14 KR KR1020137012382A patent/KR20130069855A/ko not_active Ceased
- 2011-10-14 MX MX2013004190A patent/MX346730B/es active IP Right Grant
- 2011-10-14 PL PL11833507T patent/PL2637664T3/pl unknown
- 2011-10-14 SM SM20170297T patent/SMT201700297T1/it unknown
- 2011-10-14 RS RS20170640A patent/RS56135B1/sr unknown
- 2011-10-14 NZ NZ707213A patent/NZ707213A/en active IP Right Revival
- 2011-10-14 WO PCT/US2011/056404 patent/WO2012051559A2/en not_active Ceased
- 2011-10-14 HR HRP20170848TT patent/HRP20170848T1/hr unknown
- 2011-10-17 AR ARP110103833A patent/AR083422A1/es unknown
-
2013
- 2013-04-17 ZA ZA2013/02746A patent/ZA201302746B/en unknown
- 2013-11-13 US US14/079,548 patent/US9549926B2/en active Active
-
2015
- 2015-06-10 JP JP2015117196A patent/JP2015178528A/ja not_active Withdrawn
-
2016
- 2016-07-04 AU AU2016204638A patent/AU2016204638B2/en not_active Ceased
- 2016-08-09 US US15/232,570 patent/US20160346280A1/en not_active Abandoned
-
2017
- 2017-06-22 CY CY20171100660T patent/CY1119007T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083422A1 (es) | Composiciones y metodos para tratar la hipertension pulmonar | |
| AR124134A2 (es) | Formulación de uso tópico para un inhibidor de jak | |
| ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
| CY1119817T1 (el) | Στερεα μοναδα δοσολογιας διασπωμενη στο στομα που περιεχει συστατικο οιστετρολης | |
| SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
| CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
| PE20190390A1 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| HK1247822A1 (zh) | 用於活性剂口服给药的制剂 | |
| PE20150637A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| CY1117352T1 (el) | Υποκατεστημενες ιμιδαζοπυριδαζiνες | |
| MX2014001101A (es) | Composiciones orales que contienen un ester 17-hydroxyprogesterona y metodos relacionados. | |
| PE20151501A1 (es) | Inhibidores de prmt5 y sus usos | |
| CO6680640A2 (es) | Uso de aglutinantes para fabircar formulaciones estables al almacenamiento | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| ECSP14018630A (es) | Formulaciones farmacéuticas novedosas | |
| NI201600048A (es) | Formulaciones de (s)- 3- (4-((4-(morfolinometil) bencil)oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona | |
| UY37160A (es) | COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 | |
| CL2008003181A1 (es) | Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma. | |
| CL2013000677A1 (es) | Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn. | |
| IN2014MN01919A (es) | ||
| MX2023000812A (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| CO6220902A2 (es) | Formulacion en polvo del valganciclovir | |
| AR105203A1 (es) | Formulación oral sólida que contiene irinotecán y método de preparación de la misma | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| AR096045A1 (es) | Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |